An antibody treatment study from Eli Lilly is officially over.
The National Institute of Allergy and Infectious Diseases, which sponsored the study, pulled the plug Monday.
It said there was a low chance the treatment would be helpful for patients hospitalized with COVID-19.
In the study, the antibody treatment was being used in combination with remdesivir, a drug that has been approved for emergency use to treat the coronavirus.
